Proteins are made up of long chains of amino acids. Proteins play a pivotal role in the regulation of all biological functions including DNA replication and metabolic reactions in the body. Bio-engineered proteins are developed by using genetic engineering. Bio-engineered proteins are used to treat human injury and provide effective treatments to prevent from life-threatening diseases.
The global bioengineered protein drugs market is categorized into monoclonal antibodies, cytokines, peptide hormones, vaccines, therapeutic enzymes and blood products. The cytokines segment includes interferon, interleukins and colony stimulating factors. The peptide hormone segment is sub-divided into insulin, growth hormones and erythropoietin. Vaccines include toxoid, live attenuated vaccines and killed vaccines. The therapeutic enzyme segment is further sub-segmented into digestive and metabolic enzymes. Blood products include thrombin, alpha 1-Protease inhibitor and coagulation factors.
In terms of geographic, North America and Europe dominates the global bio-engineered protein drugs market due to improved biopharmaceutical industry in the region. The U.S. represents the largest market for bio-engineered protein drugs followed by Canada in North America. In Europe, France and Germany holds major share of bio-engineered protein drugs market. However, Asia is expected to show high growth rates in the next five years in global bio-engineered protein drugs market due to improving life science research infrastructure in the region. Japan, China and India are expected to be the fastest growing bio-engineered protein drugs market in Asia.
In recent time, increasing prevalence of chronic diseases, such as cancer, diabetes and asthma is key driver for the global bio-engineered protein drugs market. For instance, according to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, an estimated 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. This increasing prevalence of chronic diseases has resulted in significant rise in demand of bio-engineered protein drugs for their treatment. In addition, advancement in manufacturing technologies is also supporting in growth of the global bio-engineered protein drugs market. However, high cost of protein drugs is key restraint for the global bio-engineered protein drugs market. Moreover, complications associated with the treatment of diseases by protein drugs also obstruct the growth of global bio-engineered protein drugs market.
Some of the major companies operating in the global bio-engineered protein drugs market are Abbott Laboratories, Allergan, Baxter International, Bayer HealthCare, Sanofi, Pfizer Inc., Johnson & Johnson, Novartis, Merck and Glaxosmithkline.
Key points covered in the report
The report covers geographic segmentation